Victory Capital Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Victory Capital Management Inc. increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 39.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,228 shares of the company’s stock after buying an additional 34,589 shares during the quarter. Victory Capital Management Inc. owned 0.26% of Pacira BioSciences worth $1,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after acquiring an additional 14,960 shares in the last quarter. Pacer Advisors Inc. raised its position in Pacira BioSciences by 37.5% in the 2nd quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock worth $61,877,000 after purchasing an additional 590,082 shares during the period. Renaissance Technologies LLC boosted its position in Pacira BioSciences by 9.8% during the second quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after buying an additional 184,000 shares during the period. Dimensional Fund Advisors LP boosted its position in Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after buying an additional 198,936 shares during the period. Finally, Doma Perpetual Capital Management LLC increased its holdings in shares of Pacira BioSciences by 71.8% in the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after buying an additional 418,321 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

PCRX stock opened at $17.55 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market capitalization of $810.28 million, a price-to-earnings ratio of -8.65 and a beta of 0.82. The firm has a 50 day moving average price of $16.21 and a 200-day moving average price of $20.30. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. HC Wainwright lowered their price objective on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.